Диссертация (1140920), страница 19
Текст из файла (страница 19)
Онкоурология 2007, 3:52-57.Морозов СП, Безруков ЕА: Томографические методы диагностикирака предстательной железы. Российский электронный журналлучевой диагностики 2011, 1(4):18-26.Котов СВ, Перов РА, Мартьянова НА, Беломытцев СВ, Юсуфов АГ,Трынов РВ, Суренков ДН, Страт АА, Сулейманов МС, Арбузов ИА:Радикальная простатэктомия у пациентов группы высокого иочень высокого риска рака предстательной железы. In: XIV КонгрессРоссийского общества урологов. Саратов; 2014: 167-168.Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H: Radicalprostatectomy for clinically advanced (cT3) prostate cancer since the11247.48.49.50.51.52.53.54.55.56.57.advent of prostate-specific antigen testing: 15-year outcome. BJUinternational 2005, 95(6):751-756.Soylu FN, Peng Y, Jiang Y, Wang S, Schmid-Tannwald C, Sethi I, EggenerS, Antic T, Oto A: Seminal vesicle invasion in prostate cancer: evaluationby using multiparametric endorectal MR imaging.
Radiology 2013,267(3):797-806.Mearini L, Zucchi A, Costantini E, Bini V, Nunzi E, Porena M: Outcomes ofradical prostatectomy in clinically locally advanced N0M0 prostatecancer. Urologia internationalis 2010, 85(2):166-172.Technical Report Series. In.: World Health Organization; 1952: 47-48.Spencer JA, Chng WJ, Hudson E, Boon AP, Whelan P: Prostate specificantigen level and Gleason score in predicting the stage of newly diagnosedprostate cancer. The British journal of radiology 1998, 71(851):1130-1135.Izumi K, Ikeda H, Maolake A, Machioka K, Nohara T, Narimoto K, Ueno S,Kadono Y, Kitagawa Y, Konaka H et al: The relationship between prostatespecific antigen and TNM classification or Gleason score in prostatecancer patients with low prostate-specific antigen levels. The Prostate2015, 75(10):1034-1042.D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, BroderickGA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ et al: Biochemicaloutcome after radical prostatectomy, external beam radiation therapy,or interstitial radiation therapy for clinically localized prostate cancer.Jama 1998, 280(11):969-974.Klaassen Z, Singh AA, Howard LE, Feng Z, Trock B, Terris MK, AronsonWJ, Cooperberg MR, Amling CL, Kane CJ et al: Is clinical stage T2cprostate cancer an intermediate- or high-risk disease? Cancer 2015,121(9):1414-1421.Gondo T, Poon BY, Matsumoto K, Bernstein M, Sjoberg DD, Eastham JA:Clinical role of pathological downgrading after radical prostatectomy inpatients with biopsy confirmed Gleason score 3 + 4 prostate cancer.
BJUinternational 2015, 115(1):81-86.Abern MR, Terris MK, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR,Freedland SJ: The impact of pathologic staging on the long-term oncologicoutcomes of patients with clinically high-risk prostate cancer. Cancer2014, 120(11):1656-1662.Huang JG, Pedersen J, Hong MK, Harewood LM, Peters J, Costello AJ,Hovens CM, Corcoran NM: Presence or absence of a positive pathologicalmargin outperforms any other margin-associated variable in predictingclinically relevant biochemical recurrence in Gleason 7 prostate cancer.BJU international 2013, 111(6):921-927.Spahn M, Briganti A, Capitanio U, Kneitz B, Gontero P, Karnes JR, SchubertM, Montorsi F, Scholz CJ, Bader P et al: Outcome predictors of radicalprostatectomy followed by adjuvant androgen deprivation in patients11358.59.60.61.62.63.64.65.66.67.with clinical high risk prostate cancer and pT3 surgical margin positivedisease.
The Journal of urology 2012, 188(1):84-90.Крашенинников АА, Сергиенко СА, Алексеев БЯ, Нюшко КМ,Калпинский АС, Воробьев НВ, Сафронова ЕЮ, Каприн АД:Результатыхирургическоголечениябольныхракомпредстательнойжелезы(РПЖ)свысокимрискомпрогрессирования.Iнациональныйконгресс"Онкологиярепродуктивных органов: от профилактики и раннего выявления кэффективному лечению"; 2016.Joniau S, Tosco L, Briganti A, Vanden Broeck T, Gontero P, Karnes RJ,Spahn M, Van Poppel H, European Multicenter Prostate Cancer C,Translational research g: Results of surgery for high-risk prostate cancer.Current opinion in urology 2013, 23(4):342-348.Lepor H: A review of surgical techniques for radical prostatectomy.Reviews in urology 2005, 7 Suppl 2:S11-17.Walsh PC, Lepor H, Eggleston JC: Radical prostatectomy withpreservation of sexual function: anatomical and pathologicalconsiderations.
Prostate 1983, 4:473–485.Schuessler WW, Schulam PG, Clayman RV, Kavoussi LR: Laparoscopicradical prostatectomy: initial short-term experience. Urology 1997,50(6):854-857.Abbou CC, Hoznek A, Salomon L, Lobontiu A, Saint F, Cicco A, AntiphonP, Chopin D: [Remote laparoscopic radical prostatectomy carried outwith a robot. Report of a case]. Progres en urologie : journal del'Association francaise d'urologie et de la Societe francaise d'urologie 2000,10(4):520-523.Phillip JG, Chun CL, Ahmedin J, Jason AE: Recent trends in themanagement of localized prostate cancer: results from the NationalCancer Data Base. J Clin Oncol 32:5s, 2014 (suppl; abstr 5066): ASCOUniversity; 2014.Evan Pollack C, Wang H, Bekelman JE, Weissman G, Epstein AJ, Liao K,Dugoff EH, Armstrong K: Physician social networks and variation in ratesof complications after radical prostatectomy.
Value in health : the journalof the International Society for Pharmacoeconomics and Outcomes Research2014, 17(5):611-618.Gacci M, Sebastianelli A, Salvi M, De Nunzio C, Schiavina R, Simonato A,Tubaro A, Mirone V, Carini M, Carmignani G: Role of abdominal obesityfor functional outcomes and complications in men treated with radicalprostatectomy for prostate cancer: results of the Multicenter ItalianReport on Radical Prostatectomy (MIRROR) study.
Scandinavian journalof urology 2014, 48(2):138-145.Tyritzis SI, Wallerstedt A, Steineck G, Nyberg T, Hugosson J, Bjartell A,Wilderang U, Thorsteinsdottir T, Carlsson S, Stranne J et al:Thromboembolic complications in 3,544 patients undergoing radical11468.69.70.71.72.73.74.75.76.77.prostatectomy with or without lymph node dissection. The Journal ofurology 2015, 193(1):117-125.Pilecki MA, McGuire BB, Jain U, Kim JY, Nadler RB: National multiinstitutional comparison of 30-day postoperative complication andreadmission rates between open retropubic radical prostatectomy androbot-assisted laparoscopic prostatectomy using NSQIP. Journal ofendourology / Endourological Society 2014, 28(4):430-436.Gandaglia G, Sun M, Trinh QD, Becker A, Schiffmann J, Hu JC, Briganti A,Montorsi F, Perrotte P, Karakiewicz PI et al: Survival benefit of definitivetherapy in patients with clinically advanced prostate cancer: estimationsof the number needed to treat based on competing-risks analysis.
BJUinternational 2014, 114(6b):E62-69.Retel VP, Bouchardy C, Usel M, Neyroud-Caspar I, Schmidlin F, Wirth G,Iselin C, Miralbell R, Rapiti E: Determinants and effects of positive surgicalmargins after prostatectomy on prostate cancer mortality: a populationbased study. BMC urology 2014, 14:86.Harty NJ, Kozinn SI, Canes D, Sorcini A, Moinzadeh A: Comparison ofpositive surgical margin rates in high risk prostate cancer: open versusminimally invasive radical prostatectomy. International braz j urol :official journal of the Brazilian Society of Urology 2013, 39(5):639-646;discussion 647-638.Shikanov S, Marchetti P, Desai V, Razmaria A, Antic T, Al-Ahmadie H,Zagaja G, Eggener S, Brendler C, Shalhav A: Short (</= 1 mm) positivesurgical margin and risk of biochemical recurrence after radicalprostatectomy.
BJU international 2013, 111(4):559-563.Izard JP, True LD, May P, Ellis WJ, Lange PH, Dalkin B, Lin DW, SchmidtRA, Wright JL: Prostate cancer that is within 0.1 mm of the surgicalmargin of a radical prostatectomy predicts greater likelihood ofrecurrence. The American journal of surgical pathology 2014, 38(3):333338.Heidenreich A, Pfister D, Porres D: Cytoreductive radical prostatectomyin patients with prostate cancer and low volume skeletal metastases:results of a feasibility and case-control study. The Journal of urology 2015,193(3):832-838.Stewart SB, Boorjian SA: Radical prostatectomy in high-risk and locallyadvanced prostate cancer: Mayo Clinic perspective. Urologic oncology2015, 33(5):235-244.Bianchi L, Gandaglia G, Fossati N, Suardi N, Moschini M, Cucchiara V,Bianchi M, Damiano R, Schiavina R, Shariat SF et al: Pelvic lymph nodedissection in prostate cancer: indications, extent and tailored approaches.Urologia 2017, 84(1):9-19.Ploussard G, Briganti A, de la Taille A, Haese A, Heidenreich A, Menon M,Sulser T, Tewari AK, Eastham JA: Pelvic lymph node dissection duringrobot-assisted radical prostatectomy: efficacy, limitations, and11578.79.80.81.82.83.84.85.86.complications-a systematic review of the literature.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
